by
Super Admin
-
2 hours from now
~ Ann Hand to Support Strategic Alternative Initiatives as Executive Chair; President Matt Edelman Promoted to the Role of Chief Executive Officer ~
by
Super Admin
-
2 hours from now
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -
by
Super Admin
-
2 hours from now
TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (together, with affiliates, “Base Carbon”, or the “Company”), is ple...
by
Super Admin
-
2 hours from now
TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Flow Capital Corp. (TSXV:FW) (“Flow Capital” or the “Company”), a leading provider of flexible growth capital and alternative debt solutions, announces $1.5 million of follow-on investments made over the...
by
Super Admin
-
2 hours from now
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) ("Prospect", “our”, or “we”) today announced that Morningstar DBRS ("DBRS") has reaffirmed Prospect’s investment grade issuer and long term senior debt credi...
by
Super Admin
-
2 hours from now
CRL focused on CMC; no clinical issues relating to etripamil raised
by
Super Admin
-
2 hours from now
MONTREAL, March 28, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) today announced financial and operational results for the fourth quarter and full year ended December 31, 2024. All amount...
by
Super Admin
-
2 hours from now
MONTRÉAL, 28 mars 2025 (GLOBE NEWSWIRE) -- Aya Or & Argent Inc. (TSX : AYA; OTCQX : AYASF) (« Aya » ou la « Société ») a annoncé aujourd’hui ses résultats financiers et opérationnels pour le quatrième trimestre et l’exercice financier term...
by
Super Admin
-
2 hours from now
SAN FRANCISCO, March 28, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, i...
by
Super Admin
-
2 hours from now
Reports Continued Progress Across Both Obesity and Oncology Franchises Reports Continued Progress Across Both Obesity and Oncology Franchises